1.. Introduction
================

In 1918, on the Greek Aegean Sea island of Skyros, the largest and southernmost island of the Northern Sporades, during the time of the celebration for Saint Demetrios, approximately one third of the whole island\'s population died of the 'Spanish' influenza pandemic in less than 30 days ([@b1-etm-0-0-7515]). Constantinos Faltaits, a prominent writer and journalist of the beginning of the last century, wrote a unique report of the Skyros flu outbreak in the whole Hellenic literature similar to Hippocrates\'s analysis of Perynthos influenza-like outbreak almost 2,400 years ago ([@b2-etm-0-0-7515]). According to his annals published in 1919, the influenza attack on Skyros island was exceptionally severe and fatal ([@b1-etm-0-0-7515]). It began on the 27th of October, 1918, and its onset was described as acute 'like a thunderbolt' and among the 3,200 inhabitants of Skyros, almost 2,000 were infected and 1,000 died ([@b1-etm-0-0-7515]). His descriptions report extremely touching details about this Greek island\'s tragedy.

At that time, the viral cause of influenza, largely targeting healthy young adults, had not been detected, while the total number of victims of the Spanish flu outbreak surpassed 50 million, worldwide. In the nearby islands of Euboea and Andros, similar family cases attacked by influenza have been reported by local writers ([@b3-etm-0-0-7515]). The deaths were in family groups, while several cases of children, who managed to survive despite losing both of their parents, have been reported. Almost one century after this Aegean Sea island tragedy, the '4th Workshop on Paediatric Virology', which was held in Athens on September 22, 2018, was dedicated to the 100 years of the 'Spanish' flu pandemic on Skyros island ([@b4-etm-0-0-7515]). This workshop was organized by the Paediatric Virology Study Group (PVSG) in the context of the 23rd World Congress on Advances in Oncology and the 22nd International Symposium on Molecular Medicine. Its educational programme focused on two viral infections with great paediatric interest, influenza and human papillomavirus (HPV). The workshop was co-chaired by Professor Tina Dalianis, Professor of Tumour Virology at Karolinska Institutet (Stockholm, Sweden), Professor Maria Theodoridou, Emerita Professor of Paediatrics at the 'Aghia Sophia' Children\'s Hospital in Athens, President of the National Immunisation Committee and former President of the Hellenic Paediatric Infectious Diseases Society (Greece), Dr Prakash Thiagarajan, Clinical Director and Consultant Neonatologist at Noble\'s Hospital on the Isle of Man (British Isles) and Ioannis N. Mammas, Consultant Paediatrician on the island of Euboea (Greece) and Coordinator of the Paediatric Virology Study Group (PVSG). This review article highlights the plenary and key lectures presented at the workshop on the recent advances on the epidemiology, clinical management and prevention of influenza in childhood ([Table I](#tI-etm-0-0-7515){ref-type="table"}).

2.. Overview of influenza vaccination in children
=================================================

Immunization against seasonal influenza has proven to be the most effective method for the prevention of the illness offering the best defence to children against acquiring the infection and spreading it to others ([@b5-etm-0-0-7515]--[@b7-etm-0-0-7515]). Immunization against seasonal influenza can reduce medical visits and missed school days and can prevent influenza-related hospitalizations and deaths in children ([@b7-etm-0-0-7515]). Historically, the first universal influenza vaccination for school children was implemented in Japan in 1962 in order to prevent influenza epidemics in the community ([@b5-etm-0-0-7515]). This strategy was abandoned in 1994. In the following years, it was well demonstrated that the protection of the older population by herd immunity was generated by the policy of universal vaccination of school children ([@b8-etm-0-0-7515]). Over the past decades, the recommendations for children\'s influenza vaccination have gradually changed and the target population has been expanded ([@b9-etm-0-0-7515]). The vaccination policy differs between countries, such as the USA, Canada and the UK. These large developed countries have issued recommendations for the vaccination of healthy children and adolescents of varying ages. It is worth noting that for the first time in 2004, healthy children aged 6--23 months of age were included in increased risk group. Currently, the influenza vaccine is recommended for healthy children of all ages. However, the majority of European countries, including Greece, have issued their own programmes implementing the approach of targeting groups at the highest risk of complications ([@b10-etm-0-0-7515]).

The influenza vaccines are multivalent and contain different viral subtypes. The composition is continuously changed in the anticipation of the expected prevalent influenza strains. The vaccines have a long history of safety in children, while prospective studies have evaluated the efficacy and immunogenicity. Children \<2 years of age seem to have an inferior immunological response than those \>2 years of age ([@b11-etm-0-0-7515]). The clinical effectiveness of influenza vaccines varies by year and setting. An important factor is related to how closely the vaccines are matched against circulating strains. The vaccines currently available are the trivalent inactivated influenza vaccines (IIV), the live attenuated influenza vaccine (LAIV) and recently, the quadrivalent IIV and the quadrivalent nasal spray LAIV; the last two formulations include two influenza B strains in addition to the A strains.

The history of influenza is characterized by a continuous effort to develop vaccines effective for the needs of the recipients. Nevertheless, the uptake of the vaccine even in high-risk children remains very low ([@b5-etm-0-0-7515]). The main reasons for the inadequate vaccine coverage are the concerns regarding the safety and effectiveness of the vaccine ([@b12-etm-0-0-7515]). A new promising era is maternal immunization. The vaccine uptake from pregnant women has the potential to change the epidemiology of influenza infection and improve maternal and neonatal health ([@b13-etm-0-0-7515]). The future perspectives for influenza include vaccines providing broader and long-lasting protection and the most important regain of public confidence to immunization.

3.. Management of influenza with antiviral drugs
================================================

Antiviral medications play a key role in the clinical management of children with influenza, and may prove to be beneficial, particularly in the hospital setting ([@b14-etm-0-0-7515]--[@b21-etm-0-0-7515]). Antiviral therapy has been associated with the prevention of disease or complications among patients exposed to the virus, a shortened duration of illness among acutely-ill patients and the reduction of morbidity and mortality among patients with severe infection ([@b22-etm-0-0-7515]). A high index of suspicion should be maintained for the diagnosis of antiviral-resistant influenza, particularly among immunocompromised patients, patients with treatment failure or progressive infection despite adequate therapy or contacts of individuals known to be infected with resistant strains, although evidence of the relative efficacy to choose between the available antiviral medications is limited ([@b23-etm-0-0-7515]). Safety information and side-effect profiles are also limited for some of these drugs.

The use of the available antiviral drugs for the treatment of influenza, Oseltamivir, Zanamavir (inhaled and injectable, Peramavir (parenteral) and Amantadine, is based on the patient (whether high-risk or not), the type of infection, known resistance patters and co-morbidities in the patients ([@b14-etm-0-0-7515]). Drugs such as Peramavir remain unlicensed in children, but have been granted special permission by the US Food and Drug Administration (FDA) for use in an outbreak. Recent influenza A viruses are resistant to Amantadine, and thus it cannot be currently recommended. All patients with complicated or progressive influenza, including children at all ages, should be treated with antiviral drugs, regardless of the risk factors and immune status. The pharmacological properties, dosage, side-effects and mode of actions for the major antiviral drugs are summarized in [Table II](#tII-etm-0-0-7515){ref-type="table"}. For hospitalized infants and children, antiviral therapy should be commenced as soon as influenza is clinically suspected or at least within 48 h from the onset of the illness. The algorithm presented in [Fig. 1](#f1-etm-0-0-7515){ref-type="fig"} is a useful decision-making tool for deciding whether to commence antiviral medication and if so, to select the correct one.

4.. Epidemiology of influenza in childhood
==========================================

Seasonal influenza is an acute viral infection that spreads efficiently from individual to individual, particularly among children that are nowadays considered to be the main drivers of influenza infection ([@b24-etm-0-0-7515]). In terms of transmission and spread, seasonal influenza is rapidly transmitted in crowded areas, particularly in schools and nurseries. When an infected person coughs or sneezes, infectious droplets are dispersed through the air and infect close contacts directly or indirectly through contaminated surfaces ([@b25-etm-0-0-7515]). Children are considered to be super-spreaders that may disperse higher viral loads and for longer time periods. In temperate climates, seasonal epidemics occur mainly during winter. Currently there are two types of influenza viruses that cause outbreaks and seasonal epidemics: types A and B. Influenza A viruses are divided into subtypes, based on the type of haemagglutinin and neuraminidase, which are the two external glycoproteins and the main antigens of the virus. Currently, co-circulating in humans are two influenza A subtypes ([Table III](#tIII-etm-0-0-7515){ref-type="table"}): A(H1N1)pdm09 and A(H3N2), and two influenza B lineages: B/Yamagata and B/Victoria ([@b25-etm-0-0-7515]). Each year, different combinations of influenza types/subtypes co-circulate and dominate. The variability of the circulating strains and differences in their genetic and antigenic characteristics drive the re-evaluation of the influenza vaccine for each season by the World Health Organization (WHO).

Seasonal influenza is a public health concern, as it is present worldwide and affects individuals of any age group. To date, research has focused on identifying which types and subtypes mostly circulate among children ([@b25-etm-0-0-7515]--[@b32-etm-0-0-7515]). It is considered that the epidemiology of seasonal influenza is indeed affected by age and the previous immunity patterns of the individuals. The youngest age groups are usually the most affected ([@b27-etm-0-0-7515],[@b28-etm-0-0-7515]), while the \<5 and the \>65 years age groups have a higher risk of severe outcomes due to influenza infections. The 5--14 year age group has been shown to be more likely infected by influenza type B viruses, while the 15--64 year age group by influenza type A viruses ([@b27-etm-0-0-7515]). As regards the influenza A subtypes, it has been shown that A(H1N1)pdm09 mostly affects the younger age groups, while A(H3N2) the older age groups ([@b31-etm-0-0-7515]). In another report, it was demonstrated that B/Victoria viruses are more common among younger age groups than B/Yamagata viruses ([@b32-etm-0-0-7515]). On the other hand, it has been concluded that the clinical presentation of disease is similar among those patients that consulted general practitioners irrespective of the influenza type from which they were infected ([@b29-etm-0-0-7515],[@b31-etm-0-0-7515]).

5.. Chest radiology issues of influenza in children
===================================================

Influenza can cause severe morbidity and mortality in previously healthy children, projecting with respiratory and less often, central nervous system disease ([@b33-etm-0-0-7515]--[@b36-etm-0-0-7515]). Influenza A viruses are an important cause of pandemic respiratory disease ([@b37-etm-0-0-7515]). For the adult patients affected, a chest radiography provides adequate information, revealing ground-glass opacities, areas of consolidation or a mixed pattern of both. However, abnormal chest radiographs are rather uncommon in children with a mild and self-limited clinical course ([@b33-etm-0-0-7515]). High-resolution computed tomography (HRCT) of the chest is of substantial value when the radiographic findings are subtle and in the assessment of complications ([@b34-etm-0-0-7515]--[@b37-etm-0-0-7515]). HRCT usually reveals peribronchial markings with hyper-inflation and ill-defined patchy consolidation with mediastinal lymph node enlargement, pleural effusion and pneumomediastinum ([@b33-etm-0-0-7515],[@b34-etm-0-0-7515]). In children with a more severe clinical course bilateral, symmetrical and multifocal areas of consolidation, often associated with ground-glass opacities, with peribronchial or subpleural distribution, are the predominant radiographical finding, evident even on chest radiographs ([@b36-etm-0-0-7515]). Albeit these findings are non-specific of influenza infection, bilateral and usually peripheral, subpleural, peribronchial and sometimes lobular pattern of distribution should raise the suspicion in presence of the corresponding clinical scenario ([@b35-etm-0-0-7515],[@b36-etm-0-0-7515]). Rarely, parenchymal abnormalities are diffuse or even unilateral ([@b33-etm-0-0-7515]--[@b36-etm-0-0-7515]). Bilateral widespread consolidation is usually associated with severe prognosis ([@b37-etm-0-0-7515]). The pattern of scattered consolidation should be differentiated from secondary bacterial pneumonia, based on the clinical and laboratory findings. A note is made of the understudied lung pattern during the recovery phase, when multifocal areas of consolidation may be demonstrated and should be differentiated from secondary bacterial infection ([@b37-etm-0-0-7515]). Even in cases of benign evolution, the consolidations may progress to chronic sequelae, such as linear opacities or air-trapping, which may reflect organizing pneumonia or bronchiolitis, respectively ([@b37-etm-0-0-7515]).

6.. Neurological complications of influenza in children
=======================================================

Neurological complications are reported in 10% of children hospitalized with influenza; these include the potentially fatal acute necrotizing encephalopathy (ANE), encephalopathy/encephalitis, seizures, Guillain-Barré syndrome, myelitis, stroke and Reye syndrome ([@b33-etm-0-0-7515],[@b38-etm-0-0-7515]). Seizures are the most common neurological complication followed by encephalitis/encephalopathy ([@b38-etm-0-0-7515]--[@b40-etm-0-0-7515]). ANE, first described in 1995 in Japan, is the most severe form of acute non-inflammatory encephalopathy, representing a more recently described para-infectious condition, considered to differ from the classical acute disseminated encephalomyelitis (ADEM). Patients present with acute and rapid neurological deterioration and often intractable seizures preceded by febrile illness. It has been most often associated with influenza infections (A/H1N1 and A/H3N2), but other viruses have also been reported to serve as a triggering factor ([@b33-etm-0-0-7515]). ANE carries a high morbidity and mortality rate (30%) and it is reported to develop in 1% of the children with influenza and neurologic complications ([@b38-etm-0-0-7515]--[@b40-etm-0-0-7515]). The majority of survivors present severe neurodevelopmental morbidity.

Imaging patterns are typical with evidence of bilateral, symmetrical areas of necrosis and haemorrhage in the thalami, the basal ganglia and occasionally the brain stem, and additional diffuse or focal areas of oedema in the cerebral and cerebellar white matter ([@b38-etm-0-0-7515]). On apparent diffusion coefficient maps, there is a laminar, target or tricolour pattern of involvement of the thalami ([@b39-etm-0-0-7515]). Overall, in a child with acute encephalopathy and bilateral symmetrical involvement of the thalami, putamen, internal capsule, brainstem, cerebellum and periventricular white matter, the suspicion for ANE should be raised. This is associated with vasculopathy and the breakdown of the blood-brain barrier; however, the detailed pathogenesis remains uncertain. Emphasis should be made regarding the need for a high index of suspicion to establish early diagnosis together with the generalized measures to prevent influenza outbreak ([@b40-etm-0-0-7515]).

7.. Myocarditis and influenza in children
=========================================

Myocarditis is an inflammatory condition of the heart muscle that can result from various aetiologies, such as autoimmune disorders, bacterial, fungal or protozoal infections, and viruses that are its most common cause ([@b41-etm-0-0-7515]--[@b43-etm-0-0-7515]). In paediatric patients, fulminant myocarditis corresponds to 30--40% of the cases of myocarditis and has a mortality rate of up to 48% ([@b44-etm-0-0-7515]). The exact prevalence of myocarditis is not known ([@b45-etm-0-0-7515],[@b46-etm-0-0-7515]). The annual incidence of dilated cardiomyopathy in children younger than 18 years is reportedly 0.57 cases/100,000 per year, while 46% of them were diagnosed as being caused by myocarditis ([@b47-etm-0-0-7515]). Hence, the incidence of myocarditis in children could be estimated as approximately 0.3 cases/year per 100,000 children. Myocardial involvement in infections by influenza ranges from 0 to 11%, depending on the criteria used to define myocarditis ([@b48-etm-0-0-7515]). Influenza A virus subtype H1N1, which was responsible for the 2009 influenza pandemic, plays a significant role in the pathogenesis of acute myocarditis. However, there are few cases of fulminant myocarditis due to H1N1 influenza reported in the literature, particularly in children ([@b48-etm-0-0-7515],[@b49-etm-0-0-7515]).

Children with myocarditis may present with a variety of symptoms, most of which are non-specific, including fever, myalgia, palpitations, or dyspnoea upon exertion. Surveillance reports have revealed fever and/or gastrointestinal symptoms as the most frequent initial symptoms ([@b44-etm-0-0-7515]). Children\'s clinical conditions may precipitate to haemodynamic instability, the rapid worsening of the patient\'s condition, eventually requiring biventricular mechanical support with cardiogenic shock and the potential presentation of fatal arrhythmias with sudden death. Importantly, myocarditis may be the cause of dilated cardiomyopathy through inflammatory autoimmune processes ([@b50-etm-0-0-7515]). Until recently, the confirmatory diagnostic procedure for myocarditis was endomyocardial biopsy; however, it has now been replaced by the cardiac magnetic resonance imaging (MRI) ([@b51-etm-0-0-7515],[@b52-etm-0-0-7515]). Echocardiography plays a paramount role in the diagnosis and follow-up of myocardial dysfunction, and is able to exclude other causes of heart failure, such as congenital heart disease and valvular or pericardial diseases, and helps to identify the fulminant course of the disease. Findings include global left ventricular dysfunction with or without pericardial effusion, a variable degree of myocardial dilation and atrioventricular valvular regurgitation.

The treatment of paediatric myocarditis consists of medications that significantly improve left ventricular systolic dysfunction. Recommendations in paediatric patients ([@b53-etm-0-0-7515]--[@b55-etm-0-0-7515]) emphasize that supportive medical therapy should be the primary therapy for acute presentation. The treatment of heart failure and left ventricular dysfunction should proceed according to the established guidelines of the American Heart Association (AHA), the American College of Cardiology and the European Society of Cardiology ([@b56-etm-0-0-7515],[@b57-etm-0-0-7515]). These guidelines suggest angiotensin-converting enzyme inhibition for asymptomatic left ventricular dysfunction), treatment implementation with selective β-blocker in symptomatic heart failure, and the use of inotropic agents with mechanical ventilatory or circulatory support for patients with rapid clinical deterioration. High-dose intravenous immunoglobulin, antiviral and antibacterial therapies may also be of therapeutic benefit.

8.. Influenza as a cause of admission to the PICU
=================================================

Influenza viruses cause a significant disease burden and due to the associated complications, children with influenza may require admission to the Paediatric Intensive Care Unit (PICU) ([@b58-etm-0-0-7515],[@b59-etm-0-0-7515]). Children at a higher risk of complications are considered to be those under 59 months of age and with concomitant medical conditions (cardiac, pulmonary, renal, metabolic, neurodevelopmental, liver and haematological diseases), or suffer from immunosuppression, such as patients with HIV/AIDS, malignancies, or those receiving chemotherapy, or steroids ([@b60-etm-0-0-7515],[@b61-etm-0-0-7515]). According to the data from the Centers for Disease Control and Prevention (CDC), 172 influenza-related paediatric deaths were reported in the USA during the season 2017--2018 ([@b62-etm-0-0-7515],[@b63-etm-0-0-7515]). During the same period, the similar national centre in Greece recorded 111 cases of severe influenza infection, among which 9 cases in children and adolescents and 42 deaths, 1 in a child \<5 years old ([@b64-etm-0-0-7515]).

Seasonal influenza, similar to other viral infections, significantly contributes to the expression of acute respiratory distress syndrome (ARDS), which represents the leading cause of admissions to the PICU ([@b65-etm-0-0-7515]). Other complications requiring admission to the PICU are myocarditis ([@b66-etm-0-0-7515]), life-threatening arrhythmias and neurological disorders, ranging from simple febrile convulsions to more severe encephalitis/encephalopathy. Influenza-associated encephalopathy is characterized by an altered level of consciousness and seizure activity within a few days of symptom onset and is rapidly progressive ([@b62-etm-0-0-7515]). Other neurological disorders include ANE, Guillain-Barre syndrome, traverse myelitis and Reye syndrome in individuals receiving acetylsalicylic acid ([@b67-etm-0-0-7515]). Rhabdomyolysis is another more severe manifestation, which can lead to acute renal failure and the need for renal replacement therapy ([@b65-etm-0-0-7515]). As presented in [Table IV](#tIV-etm-0-0-7515){ref-type="table"}, during the period 2011--2018, at 'P. and A. Kyriakou' Children\'s Hospital in Athens, Greece, among the 17 children admitted to the PICU due to complications from influenza infection (confirmed by the laboratory), 7 (41%) children experienced central nervous system disorders - 3 febrile convulsions, 2 ANE and 2 non-specific encephalopathy ([@b58-etm-0-0-7515]). Respiratory distress was responsible for 6 (35%) of admissions, half of which among children with co-morbidities, whereas 4 patients mentioned cardiovascular symptoms. Influenza A was confirmed in the majority of cases (12 children, 70,5%). No death was recorded during hospitalization, although 5 patients developed permanent defects.

9.. Paediatric healthcare workers and vaccination against influenza
===================================================================

Seasonal influenza is responsible for \>500,000 deaths each year and 3--5 million cases annually ([@b68-etm-0-0-7515]--[@b71-etm-0-0-7515]). Children are considered as vectors for the spread of influenza ([@b70-etm-0-0-7515],[@b72-etm-0-0-7515]). Healthcare workers (HCWs) are exposed to patients with influenza in the workplace; thus, they are at risk of occupationally-acquired influenza that may be transmitted to their patients and other colleagues, more frequently than the general population ([@b68-etm-0-0-7515],[@b69-etm-0-0-7515],[@b73-etm-0-0-7515],[@b74-etm-0-0-7515]). It has been reported that the annual incidence of infection among unvaccinated HCWs is 3-fold higher than among those vaccinated ([@b68-etm-0-0-7515],[@b69-etm-0-0-7515],[@b75-etm-0-0-7515]). To date, it has been well demonstrated that the immunization of HCWs against seasonal influenza indirectly protects the health of their patients, particularly those who are at high-risk, including infants, pregnant women, the elderly and the immunocompromised ([@b74-etm-0-0-7515],[@b76-etm-0-0-7515]). However, despite recommendations, as well as evidence on the efficacy of the vaccine, the coverage rate among HCWs remains unacceptably low, with a wide variation among countries (i.e., 53% in the UK vs. 5% in Poland) ([@b68-etm-0-0-7515]--[@b70-etm-0-0-7515]). Still, the main reason for HCWs to receive the influenza vaccine, even in paediatric hospitals, is self-protection and secondly the protection of their patients ([@b74-etm-0-0-7515],[@b76-etm-0-0-7515]). Paediatricians seem to have a different attitude towards vaccination and a better knowledge compared with colleagues of other specialties ([@b68-etm-0-0-7515]--[@b70-etm-0-0-7515]). Despite these differences, their participation to the seasonal influenza programme, even at the hospital settings, remains extremely low ([@b76-etm-0-0-7515]).

Thus far, the enforcement of mandatory immunization policies has achieved high coverage rates against influenza among paediatric HCWs ([@b68-etm-0-0-7515]). However, the most feasible practice seems to be the adoption of novel strategies and interventions that aim in changing behaviour against 'vaccine hesitancy', establishing scientific evidence and integrated health programme planning models ([@b69-etm-0-0-7515],[@b73-etm-0-0-7515],[@b77-etm-0-0-7515]). An increased coverage can be achieved when better information and education is given regularly to the staff and at the same time easy, free and scheduled access to the vaccination is provided ([@b69-etm-0-0-7515],[@b70-etm-0-0-7515],[@b74-etm-0-0-7515],[@b76-etm-0-0-7515]). High coverage among paediatric HCWs may also lead to the increased coverage of children against influenza. Not surprisingly, there is a strong correlation between the vaccination status against seasonal influenza of the paediatric staff and the recommendation of the vaccines to children ([@b71-etm-0-0-7515]). Paediatric HCWs are the main referents for the vaccine related information, have positive influence to the families and they can act as vaccination advocates ([@b71-etm-0-0-7515]). Educational programmes that provide information about the benefits of the immunization, clarify fears and misconceptions about the vaccines and moreover easy access to the vaccine are expected to help to reverse the low coverage rate among HCWs.

10.. Probiotics and influenza in childhood
==========================================

Probiotics are defined as live microorganisms which, when administered in adequate amounts, confer a health benefit on the host ([@b78-etm-0-0-7515]). The respiratory tract is a suitable area for probiotic immune stimulation, as its mucosal surfaces are functionally linked to the common mucosal-associated lymphoid tissues. Over the past few years common viral infections, such as influenza, have been proposed as fairly new targets for probiotics ([@b78-etm-0-0-7515]--[@b80-etm-0-0-7515]).

On the basis of the available evidence, it appears that probiotics, at least those investigated thus far in clinical trials, when administered at adequate doses for at least 30 days, can decrease the incidence and duration of influenza, as well as decrease the severity of the symptoms in adults ([@b80-etm-0-0-7515],[@b81-etm-0-0-7515]). Apart from one small trial in Japan ([@b82-etm-0-0-7515]), to date, there are no trials conducted in children for the potential benefits of probiotics specifically for the influenza virus, at least to the best of our knowledge. According to the most recent Cochrane review ([@b83-etm-0-0-7515]), probiotics seem to be more effective than placebos in reducing the number of participants, who experience episodes of acute upper respiratory tract infection (URTI), the mean duration of an episode of acute URTI, antibiotic use and cold-related school absence. A systematic review and meta-analysis of 23 randomised controlled trials involving 6,269 children with URTI concluded that children supplemented with probiotics had fewer numbers of days of URTIs per person compared with children who had taken a placebo and had fewer numbers of days absent from day care/school. However, there was no statistically significant difference in the illness episode duration between probiotic intervention group and placebo group ([@b84-etm-0-0-7515]). On the other hand, a systematic review and a network meta-analysis ([@b85-etm-0-0-7515],[@b86-etm-0-0-7515]) regarding the benefit of probiotics in children with URTI found a lack of evidence to support the effect of probiotics on the incidence rate of respiratory infections in children and adolescents. It can be concluded that the current data are contradictory, and somewhat insufficient to strongly recommend their routine use ([@b87-etm-0-0-7515]).

As regards the influenza vaccination, there is also evidence from recent systematic reviews and meta-analysis for the beneficial effects of prebiotic/probiotic supplementation on the immunological response to influenza vaccine in adults ([@b88-etm-0-0-7515],[@b89-etm-0-0-7515]). The use of adjuvant prebiotics/probiotics may offer an inexpensive intervention that may contribute to the prevention of influenza following influenza vaccination. However, a high heterogeneity of existing evidence was noted, while there are no reports to date that include children, at least to the best of our knowledge ([@b90-etm-0-0-7515],[@b91-etm-0-0-7515]). Further studies are warranted, particularly in children, to elucidate the effectiveness of probiotics in the prevention of influenza and decide on the optimal strains, dose, and the timing and duration of supplementation, since there are many strains of probiotics with established immune modulatory effects yet to be tried.

The authors would like to thank all the participants, who attended the workshop and provided feedback so that further work on improving the programme can be achieved in the future.
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###### 

The top key messages of the '4th Workshop on Paediatric Virology' on paediatric influenza.

  --------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Prevention of influenza     Immunization against seasonal influenza has proven to be the most effective method for the prevention of the illness and is crucial both to protect children and to indirectly protect the vulnerable population.
                              Educational programmes that provide information about the benefits of the immunization, clarify fears and misconceptions about the vaccines and moreover easy access to the vaccine, may help to reverse the low coverage rate among HCWs and children as well.
  Management of influenza     Antiviral medications play a key role in the clinical management of children with influenza, particularly in the hospital setting.
                              For hospitalized infants and children, antiviral therapy should be commenced as soon as influenza is clinically suspected or at least within 48 h from the onset of the illness.
  Epidemiology of influenza   To date, two influenza A subtypes, A(H1N1)pdm09 and A(H3N2), and two influenza B lineages, B/Yamagata and B/Victoria, co-circulate in humans and cause considerable morbidity and mortality in children.
  Influenza radiology         Abnormal chest radiographs are rather uncommon in children with a mild and self-limited clinical course of influenza.
                              HRCT is of substantial value when the radiographic findings are subtle and in the assessment of complications.
                              In a child with acute encephalopathy and bilateral symmetrical involvement of the thalami, putamen, internal capsule, brainstem, cerebellum and periventricular white matter the suspicion for ANE should be raised.
  Influenza and myocarditis   Seasonal influenza can cause myocarditis in children, which can be presented with fever, myalgias, palpitations, or dyspnoea on exertion.
                              In paediatric cases of fulminant progression of myocarditis, the identification of signs and symptoms suggesting greater severity should be immediate.
                              Prompt cardiological examination with the use of echocardiography is important for the early detection and follow-up of the myocardial dysfunction.
  Influenza and PICU          Influenza may cause severe disease that can be occasionally fatal, especially in high-risk groups; due to influenza\'s complications children may require admission to the Paediatric Intensive Care Unit (PICU).
  Influenza and probiotics    Further studies are required to elucidate the effectiveness of probiotics in the prevention of influenza in childhood.
  --------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HCWs, health care workers; HRCT, high-resolution computed tomography; ANE, acute necrotizing encephalopathy; PICU, Paediatric Intensive Care Unit.

###### 

Pharmacological properties, dosage, side-effects and mode of actions for the major antiviral drugs against influenza.

  Drug                     Mechanism of action        Dosage                                                                                                                                                                                                                                                                       Side-effects                                                                     Resistance profile                                                                  Remarks
  ------------------------ -------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- --------------------------------------------------
  Oseltamivir              Neuraminidase inhibition   2.5 mg/kg twice a day for children 1--3 months, 3.0 mg/kg twice a day for children 3--12 months. For 1--13 years the recommended oseltamivir dose is 30 mg, 45 mg, 60 mg or 75 mg twice a day for children weighing \<15 kg, 15--23 kg, 23--40 kg or \>40 kg, respectively   Gastrointestinal disturbances Rarely hepatitis, arrhythmia and Stevens-Johnson   Uncommon H275Y mutation in H1N1 strains More rare mutations in other subtypes       Dose reduction in renal failure
  Zanamivir                Neuraminidase inhibition   10 mg twice a day for 5 days (only for children over 5 years)                                                                                                                                                                                                                Rarely bronchospasm or angio-oedema                                              Rare I223R mutation detected in \~10 cases of H1N1 (2009) worldwide                 Can be given via intravenous route
  Peramivir (unlicensed)   Neuraminidase inhibition   Birth - 30 days, 6 mg/kg; 31 days - 90 days, 8 mg/kg; 91 days - 180 days, 10 mg/kg; 181 days - 5 years, 12 mg/kg; 6 years - 17 years, 10 mg/kg                                                                                                                               Gastrointestinal disturbances, psychiatric abnormalities, neutropenia            Rare H275Y mutation reduces efficacy                                                Dose reduction in renal failure. Unlicensed drug
  Amantadine               M2 channel inhibitor       1 to 9 years: 5 mg/kg orally per day in 2 divided doses; not to exceed 150 mg/day; 10 years or older, \<40 kg: 5 mg/kg orally per day 10 years or older, 40 kg or more: 100 mg orally twice a day                                                                            Confusion, insomnia, Exacerbation of underlying neurological conditions          Common H1N1 (2009) 100% resistant Varying rates in H3N2/seasonal H1N1/influenza B   Dose reduction in renal failure

###### 

Co-circulating influenza types in children.

  ----------------------
  Influenza A subtypes
    A(H1N1)pdm09
    A(H3N2)
  Influenza B lineages
    B/Yamagata
    B/Victoria
  ----------------------

###### 

Distribution of risk factors and complications among admissions to the PICU during the period 2011--2018 at 'P. and A. Kyriakou' Children\'s Hospital in Athens, Greece.

  Characteristics                          All patients n=17   Influenza A n=12   Influenza B n=5
  ---------------------------------------- ------------------- ------------------ -----------------
  Sex, n (%)                                                                      
    Male                                   8 (47)              6 (50)             2 (40)
    Female                                 9 (53)              6 (50)             3 (60)
  Age group, n (%)                                                                
    \<6 months                             4 (23)              4 (33)             0
    6--24 months                           4 (23)              3 (25)             1 (20)
    2--5 years                             3 (18)              3 (25)             0
    5--14 years                            6 (35)              2 (17)             4 (80)
  Chronic conditions, n (%)                                                       
    Yes                                    6 (35)              3 (25)             3 (60)
    No                                     11 (65)             9 (75)             2 (40)
  Complications, n (%)                                                            
    Febrile convulsions                    3 (18)              3 (25)             0
    Acute necrotizing encephalopathy       2 (12)              2 (17)             0
    Non-specific encephalopathy            2 (12)              1 (8)              1 (20)
    Bronchiolitis                          2 (12)              2 (17)             0
    Pneumonia                              2 (12)              1 (8)              1 (20)
    Asthma                                 1 (6)               0                  1 (20)
    ARDS                                   1 (6)               1 (8)              0
    Myocarditis                            3 (18)              2 (17)             1 (20)
    Non-specific cardiovascular symptoms   1 (6)               0                  1 (20)
  Days of PICU stay,                                                              
    Median (range)                         15.6 (1--190)       5.4 (1--18)        40.1 (1--190)

PICU, Paediatric Intensive Care Unit; ARDS, acute respiratory distress syndrome.
